BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Alourfi M, Mosli M, Saadah OI. The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn's Disease. Cureus 2020;12:e10315. [PMID: 33052277 DOI: 10.7759/cureus.10315] [Reference Citation Analysis]
2 Huang H, Wang X, Ou D, Liu X, Wu B, Zhou B, Wang Y, Shi X. Four Variants of SLCO2A1 Identified in Three Chinese Patients with Chronic Enteropathy Associated with the SLCO2A1 Gene. Dig Dis Sci 2021;66:2992-3001. [PMID: 33000396 DOI: 10.1007/s10620-020-06629-0] [Reference Citation Analysis]